Log In
BCIQ
Print this Print this
 

SYNT001

  Manage Alerts
Collapse Summary General Information
Company Syntimmune Inc.
DescriptionBiologic that blocks the FcRn-IgG interaction
Molecular Target Fc fragment of IgG receptor transporter alpha (FCRN) (FCGRT)
Mechanism of Action 
Therapeutic ModalityBiologic
Latest Stage of DevelopmentPhase I
Standard Indication Autoimmune (unspecified)
Indication DetailsTreat IgG-mediated autoimmune diseases
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today